Financials
- Fiscal year
- 2025
- Total assets
- €1.8m
- Profit
- €115,196
- Solvency
- 71.8%
Total assets▼ 11.0%
Net result
20182025
HOESELTPHARMA
ActiveSummary
HOESELTPHARMA has been active since 2010 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €1.3m and a net result of €115,196. Equity is growing by ~13.4% per year across the filed fiscal years. Its solvency ranks better than 83% of 11293 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.3% (very low).
Overview
Activity
Retail sale of pharmaceutical products
NACE 47730
1 site
Size
€1.8mtotal assets 2025
- Staff
- 3.1 FTE
- Equity
- €1.3m
- Profit
- €115,196
Turnover not published (abridged schema)
Structure
Accounts 31 d early0 of 3 deeds read
Why 88- Figures for FY 2024 (filed 27-06-2025)+ Liquidity: current ratio 2.07, cash €716,094+ Founded in 2010+ Equity €1.1m (58.1% of total assets)Show the evidence
Checked score
Score 2025
88
/ 100
Excellent
Probability in this band: under 0.55%
Better than 72% of its sector peers (NACE 47, micro)
Performance against the sector, not lower risk
Financial strength · tick = 2024
Strong
Solvency
97+14
equity 71.8% of total assets
Liquidity
88+3
short-term debt 13.1% · cash 32.2%
Profitability
77+1
return on assets 6.6%
Bankruptcy probability, 12 months
0.3%
Very low
0%0.5%1.5%4%10%≥ 25%
About 3 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 16 months
07-2025: 0.1%
08-2025: 0.1%▼ -2.4% vs 07-2025
09-2025: 0.1%● 0.0% vs 08-2025
10-2025: 0.1%▼ -5.7% vs 09-2025
11-2025: 0.1%● 0.0% vs 10-2025
12-2025: 0.1%▼ -0.9% vs 11-2025
01-2026: < 0.1%▼ -60.0% vs 12-2025lowest value
02-2026: < 0.1%● 0.0% vs 01-2026lowest value
03-2026: < 0.1%● 0.0% vs 02-2026lowest value
04-2026: < 0.1%▲ +4.3% vs 03-2026
05-2026: < 0.1%● 0.0% vs 04-2026
06-2026: 0.1%▲ +16.7% vs 05-2026
07-2026: 0.1%▲ +33.9% vs 06-2026
08-2026: 0.1%▲ +94.7% vs 07-2026
09-2026: 0.2%▲ +21.9% vs 08-2026
10-2026: 0.3%▲ +65.2% vs 09-2026highest value
- Figures for FY 2024 (filed 27-06-2025) raises the probability
- Liquidity: current ratio 2.07, cash €716,094 lowers the probability
- Founded in 2010 lowers the probability for this profile
- Equity €1.1m (58.1% of total assets) lowers the probability
Credit up to €110,000 at 30 days acceptable
Liquidity ample (current ratio 4.2 against 2.07 in 2024; short-term debt: 13.1% and cash: 32.2% of total assets), and 28.2% of the assets are financed with debt.
How it is calculated
The band comes from the bankruptcy probability on a scale of 0 to 100: every 10 points more double the odds of getting through the year without bankruptcy.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Place inside the band: half the bankruptcy probability, half how the company does against its sector peers (NACE 47, micro). Better than this share of them on solvency 71%, liquidity 88%, profitability 64%, growth against the median 63%. That is performance, not lower risk; the band itself always comes from the probability.
Bankruptcy probability: model pd-v3.202610021621, computed on 02-10-2026. The model learns from Belgian bankruptcies and reads the registers, the annual accounts and the gazette.
Ceilings: negative or zero equity, a heavy loss, a special KBO legal situation and a missing filing 59 (two missing 44), an ongoing judicial reorganisation or an ending 24. Financial strength does not count in the score.
Credit check for your own amount and term
Show the recommended maximum : and see how the verdict changes with amount, term and advance.
Signals
Five signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 30-06-2026, 31 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
31 d early
2024
34 d early
2023
34 d early
2022
on the day
2021
31 d early
2020
1 d early
2019
31 d early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
This company filed its last 7 accounts on average 23 days before the deadline; the sector median for financial year 2024 is on the deadline day, and 47% of the sector filed late.
Checked, nothing found (2)
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. Usually files around 30 June (4 of the last 5 filed years within 30 days of that day).
Companies Code · seven monthsPosition in the running window
02-10-2026 today31-12-2026 close31-07-2027 deadline
- Annual accounts filedfiscal year 2025 · abbreviated…
- Liquidity doublescurrent ratio 4.20
- Annual accounts filedfiscal year 2024 · abbreviated…
Key points
By topic
Timeline
- Events
- 14
- Since
- 2017
- Next accounts
- by 31-07-2027
- 30-06-2026Annual accounts filed
- 31-12-2025Liquidity doubles
- 27-06-2025Annual accounts filed
Company details
- Sites
- 1
- Legal form
- Private limited company
- Activity
- Retail sale of pharmaceutical productsNACE 47730
- Founded
- 17-06-2010
- Year ends
- 31-12
- Peppol
- Reachable for e-invoices
Go further with this company
How much credit can you give this customer, and on what term?Credit check What should you check before you do business with this company?Supplier due diligence Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check How does this company compare with its sector?Sector benchmark What changed in the latest annual accounts?What changed
Your own company? See how customers, suppliers and banks see it and what to improve first.
Investigating this company? Keep it with today's facts in a case file.